Current Liabilities
Accrued Expenses
Eli Lilly Accrued Expenses decreased by 42.8% to $1.36B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.0%, from $1.11B to $1.36B. Over 5 years (FY 2020 to FY 2025), Accrued Expenses shows an upward trend with a 19.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Significant fluctuations can indicate changes in operational scale, timing of payments, or shifts in compensation structures.
Detailed definition
This represents liabilities for expenses that have been incurred by the company but have not yet been paid or invoiced....
Peer comparison
Standard operating liability found in almost all corporate balance sheets, reflecting normal business cycle timing.
Metric ID:
accrued_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $755.5M | $836.6M | $958.1M | $693.1M | $835.8M | $984.1M | $1.06B | $739.7M | $867.7M | $1.23B | $1.65B | $844.2M | $1.17B | $1.7B | $2.09B | $1.11B | $1.3B | $1.97B | $2.38B | $1.36B |
| QoQ Change | — | +10.7% | +14.5% | -27.7% | +20.6% | +17.7% | +7.7% | -30.2% | +17.3% | +42.1% | +33.8% | -48.8% | +38.4% | +45.8% | +22.9% | -46.8% | +17.0% | +50.9% | +20.8% | -42.8% |
| YoY Change | — | — | — | — | +10.6% | +17.6% | +10.6% | +6.7% | +3.8% | +25.3% | +55.7% | +14.1% | +34.6% | +38.1% | +26.9% | +31.9% | +11.5% | +15.4% | +13.4% | +22.0% |
Range$693.1M – $2.38B
CAGR+13.2%
Avg YoY Growth+21.2%
Median YoY Growth+16.5%
Accrued Expenses at Other Companies
Frequently Asked Questions
- What is Eli Lilly's accrued expenses?
- Eli Lilly (LLY) reported accrued expenses of $1.36B in Q1 2026.
- How has Eli Lilly's accrued expenses changed year-over-year?
- Eli Lilly's accrued expenses increased by 22.0% year-over-year, from $1.11B to $1.36B.
- What is the long-term trend for Eli Lilly's accrued expenses?
- Over 5 years (2020 to 2025), Eli Lilly's accrued expenses has grown at a 19.0% compound annual growth rate (CAGR), from $997.2M to $2.38B.
- What does accrued expenses mean?
- Expenses that have been incurred but not yet paid to vendors or employees.